Predictors of first recurrence in Clostridium difficile-associated disease. A Study of 306 patients hospitalized in a Romanian tertiary referral center

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 4, 2013, Pages 397-403

  Lupse, Mihaela ^a   Flonta, Mirela ^b   Cioara, Andreea ^a   Filipescu, Irina ^a   Todor, Nicolae ^c  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Hospital of Infectious Diseases   (Romania)

^c THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

Author keywords

Clostridium difficile associated disease; Nosocomial gastroenteritis; Recurrence; Risk factors

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; METRONIDAZOLE; PROTON PUMP INHIBITOR; VANCOMYCIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DEATH; DIARRHEA; FECES CULTURE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; ROMANIA; TERTIARY CARE CENTER; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HOSPITALIZATION; HOSPITALS, TEACHING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METRONIDAZOLE; MIDDLE AGED; PROTON PUMP INHIBITORS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; ROMANIA; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 84890481578     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Do AN, Fridkin SK, Yechouron A, et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:954-959.
2. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008;70:298-304.
3. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse aTher treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591-1597.
4. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009;136:1206-1214.
5. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20:43-50.
6. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-1017.
7. Bartlett JG. Narrative review: the new epidemic of Clostridium difficileassociated enteric disease. Ann Intern Med 2006;145:758-764.
8. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-455.
9. Rosner B. Fundamentals of biostatistics. 7th edition. Duxbury Press, Pacific Grove, CA 2010.
10. CDC, 2007. http://www.cdc.gov/ncidod/dhqp/id_Cdi_FAQ_general. html
11. Gheorghe L, Vadan R, Cerban R, Gheorghe C. Clostridium difficile infection in gastroenterology settings: more frequent or better diagnosed? J Gastrointestin Liver Dis 2012;21:110-111.
12. Depestel DD, Aronoff DM. Epidemiology of Clostridium difficile Infection. J Pharm Pract 2013;26:464-475.
13. Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper EJ, Poxton I. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterization of the isolates. Clin Microbiol Infect 2007;13:1048-1057.
14. O'Horo JC, Jindai K, Kunzer B, Safdar N. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 2013 Jul 10.
15. Debast SB, Bauer MP, Kuijper EJ; The Committee. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2013 Oct 5.
16. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5:549-557.
17. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficileassociated diarrhea. J Clin Microbiol 2000;38:2386-2388.
18. Choi HK, Kim KH, Lee SH, Lee SJ. Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization. J Korean Med Sci 2011;26:859-864.
19. Asensio A, Vaque-Rafart J, Calbo-Torrecillas F, et al; EPINE Working Group. Increasing rates in Clostridium difficile infection (CDI) among hospitalised patients, Spain 1999-2007. Euro Surveill 2008;13(31).
20. Hensgens MP, Goorhuis A, van Kinschot CM, Crobach MJ, Harmanus C, Kuijper EJ. Clostridium difficile infection in an endemic setting in the Netherlands. Eur J Clin Microbiol Infect Dis 2011;30:587-593.
21. Maroo S, Lamont JT. Recurrent Clostridium difficile. Gastroenterology 2006;130:1311-1316.
22. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut 2001;49:152-153.
23. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010;23:529-549.
24. Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012;55(Suppl 2):S77-S87.
25. Wilcox MH, Fawley WN, Settle CD, Davidson A. Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection? J Hosp Infect 1998;38:93-100.
26. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009;58:403-410.
27. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390-397.
28. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189-193.
29. Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994;62:384-389.
30. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridum difficile-associated diarrhea. J Infect Dis 2008;197:435-438.
31. Kim JW, Lee KL, Jeong JB, et al. Pro¬ton pump inhibitors as a risk factor for recurrence of Clostridium difficile-associated diarrhea. World J Gastroenterol 2010;16:3573-3577.
32. Tal S, Gurevich A, Guller V, Gurevich I, Berger D, Levi S. Risk factors for recurrence of Clostridium difficile-associated diarrhea in the elderly. Scand J Infect Dis 2002;34:594-597.
33. Leav BA, Blair B, Leney M, et al. Serum anti-tox¬in B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010;28:965-969.
34. Jung KS, Park JJ, Chon YE, et al. Risk factors for treatment failure and recurrence aTher metronidazole treatment for Clostridium difficileassociated diarrhea. Gut Liver 2010;4:332-337.
35. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid suppressive agents and the risk of community-acquired Clostridium difficileassociated disease. JAMA 2005;294:2989-2995.
36. Cadena J, Thompson GR 3rd, Patterson JE, et al. Clinical predictors and risk factors for re¬lapsing Clostridium difficile infection. Am J Med Sci 2010;339:350-355.
37. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009;15:1554-1580.
38. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 2012;18:21-27.
39. Wilson KH, Sheagren JN, Freter R. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J Infect Dis 1985;151:355-361.
40. Bauer MP, Kuijper EJ, van Dissel JT; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009;15:1067-1079.
41. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol 2004;38:414-418.
42. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006;42:758-764.
43. Bouza E, Dryden M, Mohammed R, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea. Clin Microbiol Infect 2008;14:S103-S104.
44. Abdel Samie A, Traub M, Bachmann K, Kopischke K, Theilmann L. Risk Factors for Recurrence of Clostridium Difficile-associated Diarrhea. Hepatogastroenterology 2013;60:126.
45. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281-289.
46. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205.
47. Johnson S, Gerding DN, Louie TJ, Ruiz NM, Gorbach SL. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 2012;56:4043-4045.
48. Miller MA, Louie T, Mullane K, et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis 2013;13:148.